|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM331053373 |
| 003 |
DE-627 |
| 005 |
20231225212624.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108859
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1103.xml
|
| 035 |
|
|
|a (DE-627)NLM331053373
|
| 035 |
|
|
|a (NLM)34563685
|
| 035 |
|
|
|a (PII)S1521-6616(21)00196-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a de Araújo, Thádia Evelyn
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Long-term impact of congenital toxoplasmosis on phenotypic and functional features of circulating leukocytes from infants one year after treatment onset
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.11.2021
|
| 500 |
|
|
|a Date Revised 26.11.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Changes in immune response of children with congenital toxoplasmosis (CT) regarding infection evolution and therapeutic intervention was addressed. Infants with CT presented increased counts of monocytes, CD3-CD16-CD56High, CD3+CD56+ and CD4+ T-cells 1-year after treatment onset (TOXO1-yearAT). Smaller numbers of CD3-CD16-CD56+ and TCRγδ+ T-cells were specifically observed in infants with retinochoroidal lesions (L(+)). When infants were classified based on the baseline status, expansion of CD3-CD16-CD56High and CD4+ T-cells were observed in L(+) who had active, active/cicatricial or cicatricial lesions. Infants who had active or active/cicatricial lesions display augmented numbers of monocytes, CD3-CD16+CD56+, CD3+CD56+, CD8+DR+ and TCRγδ+ T-cells and those with active/cicatricial or cicatricial at baseline displayed increase in CD14+CD64+ monocytes. Moreover, all L(+) had increased IFN-γ+ and IL-10+ CD4+ T-cells, while L(-) had increased ratios of TNF+, IFN-γ+ and IL-4+ NK-cells upon antigen-specific stimulation. Persistent alterations in leukocytes in TOXO1-yearAT suggest long-term sequels in the immune system of infants with CT
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Observational Study
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Congenital
|
| 650 |
|
4 |
|a Immune response
|
| 650 |
|
4 |
|a Infants
|
| 650 |
|
4 |
|a Phenotypic and functional biomarkers
|
| 650 |
|
4 |
|a Toxoplasmosis
|
| 650 |
|
7 |
|a Antiprotozoal Agents
|2 NLM
|
| 650 |
|
7 |
|a Sulfadiazine
|2 NLM
|
| 650 |
|
7 |
|a 0N7609K889
|2 NLM
|
| 650 |
|
7 |
|a Pyrimethamine
|2 NLM
|
| 650 |
|
7 |
|a Z3614QOX8W
|2 NLM
|
| 700 |
1 |
|
|a Gomes, Angelica Oliveira
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Coelho-Dos-Reis, Jordana Grazziela
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Carneiro, Ana Carolina Aguiar Vasconcelos
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Machado, Anderson Silva
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Andrade, Gláucia Manzan Queiroz
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vasconcelos-Santos, Daniel Vitor
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Januário, José Nélio
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peruhype-Magalhães, Vanessa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Teixeira-Carvalho, Andréa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vitor, Ricardo Wagner Almeida
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Antonelli, Lis Ribeiro do Valle
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ferro, Eloisa Amalia Vieira
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Martins-Filho, Olindo Assis
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a UFMG Congenital Toxoplasmosis Brazilian Group - UFMG-CTBG
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Machado Azevedo, Danuza O
|e investigator
|4 oth
|
| 700 |
1 |
|
|a Machado Carellos, Ericka V
|e investigator
|4 oth
|
| 700 |
1 |
|
|a Resende, Luciana Macedo
|e investigator
|4 oth
|
| 700 |
1 |
|
|a Castro Romanelli, Roberta M
|e investigator
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 232(2021) vom: 01. Nov., Seite 108859
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:232
|g year:2021
|g day:01
|g month:11
|g pages:108859
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108859
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 232
|j 2021
|b 01
|c 11
|h 108859
|